Evidence map›Paper›PMID 19967777›Full record

ArticleJournal of pharmaceutical sciences2010

Swellable microparticles as carriers for sustained pulmonary drug delivery.

Ibrahim M El-Sherbiny, Shayna McGill, Hugh D C Smyth

Abstract read
In one paragraph

Article in Journal of pharmaceutical sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Aerosol pulmonary immune engineering.Advanced drug delivery reviews · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016
    Review
  16. Article
  17. Inhaled nano- and microparticles for drug delivery.Global cardiology science & practice · 2015
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ibrahim M El-SherbinyDivision of Pharmaceutical Sciences, College of Pharmacy, University of New Mexico, Albuquerque, New Mexico 87131, USA.
Shayna McGill
Hugh D C Smyth

Funding

Multifunctional nanoparticles: Nano-knives and nano-pullies for enhanced drug delR21HL092812 · NHLBI · UNIVERSITY OF TEXAS AT AUSTIN · PI SMYTH, HUGH DAVID · 2010 to 2011
$718k
Sustained Release Pulmonary Delivery for Improved Cystic Fibrosis TreatmentR03EB006892 · NIBIB · UNIVERSITY OF NEW MEXICO · PI FELTON, LINDA A. · 2007 to 2008
$149k
NHLBI NIH HHS R21 HL092812NIBIB NIH HHS EB006892ANIBIB NIH HHS R03 EB006892
6 · The paper itself

Abstract

In this investigation, novel biodegradable physically crosslinked hydrogel microparticles were developed and evaluated in vitro as potential carriers for sustained pulmonary drug delivery. To facilitate sustained release in the lungs, aerosols must first navigate past efficient aerodynamic filtering to penetrate to the deep lung (requires small particle size) where they must then avoid rapid macrophage clearance (enhanced by large particle size). The strategy suggested in this study to solve this problem is to deliver drug-loaded hydrogel microparticles with aerodynamic characteristics allowing them to be respirable when dry but attain large swollen sizes once deposited on moist lung surfaces to reduce macrophage uptake rates. The microparticles are based on PEG graft copolymerized onto chitosan in combination with Pluronic(R) F-108 and were prepared via cryomilling. The synthesized polymers used in preparation of the microparticles were characterized using FTIR, EA, 2D-XRD, and differential scanning calorimetry (DSC). The microparticles size, morphology, moisture content, and biodegradation rates were investigated. Swelling studies and in vitro drug release profiles were determined. An aerosolization study was conducted and macrophage uptake rates were evaluated against controls. The microparticles showed a respirable fraction of approximately 15% when prepared as dry powders. Enzymatic degradation of microparticles started within the first hour and about 7-41% weights were remaining after 240 h. Microparticles showed sustained release up to 10 and 20 days in the presence and absence of lysozyme, respectively. Preliminary macrophage interaction studies indicate that the developed hydrogel microparticles significantly delayed phagocytosis and may have the potential for sustained drug delivery to the lung.

Indexed as

Administration, InhalationAerosolsAnimalsBiocompatible MaterialsBiopolymersCell LineCross-Linking ReagentsDelayed-Action PreparationsDrug CarriersDrug CompoundingFluoresceinHydrogelsLungMacrophages, AlveolarMiceMicroscopy, Electron, ScanningAerosolsBiocompatible MaterialsBiopolymersCross-Linking ReagentsDelayed-Action PreparationsDrug CarriersFluoresceinHydrogelsPharmaceutical PreparationsPolyethylene Glycols

Identifiers

PMID19967777
PMCPMC3654803

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.